Thursday Mar 6
Isis Pharmaceuticals, Inc. To Present At The Global Healthcare Conference
A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com .
Trending on the Topix Network
Thursday Mar 6
Sanofi (France) Beefs Up Salesforce To Revive Kynamro Launch
Sanofi isn't the only one hiring, others are hiring too! Check it out! What's Sanofi's answer to the sluggish launch of orphan drug Kynamro ? Put more troops on the ground.
Wed Mar 05, 2014
Tue Mar 04, 2014
The Motley Fool
Why Zynga Inc., Isis Pharmaceuticals, and Vipshop Holdings Ltd. Are Today's 3 Best Stocks
The S&P notched a new record high at the market close today, gaining 1.3% on a day when most stocks across the market surged into the green in a big way.
Mon Mar 03, 2014
Applied Clinical Trials
ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
Isis Pharmaceuticals Inc - 10-K - Management's Discussion and...
We are the leading company in antisense drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class drugs.
Fri Feb 28, 2014
Isis' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Welcome to the Isis Pharmaceuticals' Year End Financial Results Conference Call.
Isis Pharmaceuticals (ISIS) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Isis Pharmaceuticals announced its earnings results on Friday. The company reported earnings per share for the quarter, missing the consensus estimate of by $0.04, AnalystRatings.Net reports.
Isis Pharmaceuticals, Inc. Reports Financial Results And Highlights For 2013
Isis Pharmaceuticals, Inc. today announced its 2013 financial results and reviewed the highlights of the year.
Wed Feb 26, 2014
The San Diego Union-Tribune
The story of Isis: Science rules
Stanley Crooke, chairman and chief executive of Isis Pharmaceuticals, spoke at Biocom's fourth annual Global Life Science Partnering conference.
Ico Therapeutics: Near-Term Catalyst Presents Enormous Upside
We have decided to take a very detailed look at iCo Therapeutics and the company's Phase 2 drug for Diabetic Macular Edema , iCo-007, an anti-sense drug candidate in-licensed from ISIS Pharmaceuticals in 2005.
Mon Feb 24, 2014
Isis Pharmaceuticals, Inc. Reports Interim Results From ISIS-SMN Rx...
Isis Pharmaceuticals, Inc. Reports Interim Results From ISIS-SMN Rx Phase 2 Study In Infants With Spinal Muscular Atrophy /PRNewswire/ -- Isis Pharmaceuticals, Inc. today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy .
Five Star Equities Issues New Research Reports on ACAD, IDRA, ISIS...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Fri Feb 21, 2014
Friday's ETF Movers: XBI, GDXJ
In trading on Friday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.8% on the day.
A Biotech Bubble? Maybe Not
High flying biotech ETFs flew higher Friday, as major market indices shrank, thanks in part to positive news regarding an experimental drug being development by Isis Pharmaceuticals and its much-bigger partner, Biogen-Idec .
Mid-Day Market Update: Acacia Research Shares Decline On Downbeat Results; Emeritus Spikes Higher
Midway through trading Friday, the Dow traded up 0.24 percent to 16,171.28 while the NASDAQ surged 0.31 percent to 4,280.97.
Thu Feb 20, 2014
Webcast Alert: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call
What: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call When: Friday, February 28 at 11:30 a.m. ET /8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet.
Canaccord Genuity Increases Isis Pharmaceuticals Price Target to $45.00
The firm currently has a "hold" rating on the stock. Canaccord Genuity's price target indicates a potential downside of 11.94% from the company's current price.
Wed Feb 19, 2014
Gunderson Capital is initiating coverage of Isis Pharmaceuticals with ...
February 19, 2014 Gunderson Capital Research: Isis Pharmaceuticals Rated a 'Buy for the Aggressive Portfolio- Initiation of Coverage Maybe someday, someone will tell the story of how a plate of chocolate chip cookies created the San Diego biotech industry.
Isis Pharmaceuticals, Inc. To Present At The 2014 Global Healthcare Conference
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com .